Evidence map›Paper›PMID 42033239›Full record

ArticleGut microbes2026

EB1010, a putative Christensenellaceae-derived microbial peptide, exhibits anti-inflammatory activity and therapeutic potential in ulcerative colitis.

Maria L Orsini Delgado, Camille Baudesson de Chanville, Hélène Pfister, Laureen Bardouillet, William Farin, Philippe Rinaudo, Jessica Quessel, Francesco Strozzi, Hélène Pereira, Marc Maresca and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Maria L Orsini DelgadoDrug discovery department, Enterome, Paris, France.ORCID 0000-0003-4655-1695
Camille Baudesson de ChanvilleDrug discovery department, Enterome, Paris, France.
Hélène PfisterDrug discovery department, Enterome, Paris, France.ORCID 0000-0002-2561-0265
Laureen BardouilletDrug discovery department, Enterome, Paris, France.ORCID 0009-0000-8463-7313
William FarinDrug discovery department, Enterome, Paris, France.ORCID 0000-0002-4128-8923
Philippe RinaudoDrug discovery department, Enterome, Paris, France.
Jessica QuesselDrug discovery department, Enterome, Paris, France.
Francesco StrozziDrug discovery department, Enterome, Paris, France.ORCID 0000-0002-6845-6982
Hélène PereiraDrug discovery department, Enterome, Paris, France.
Marc MarescaAix Marseille Univ., CNRS, Centrale Marseille, iSm2, Marseille, France.ORCID 0000-0002-3585-4765
Cendrine NicolettiAix Marseille Univ., CNRS, Centrale Marseille, iSm2, Marseille, France.ORCID 0000-0002-0086-6707
Eric Di PasqualeInstitut de NeuroPhysioPathologie (INP), Aix Marseille Université, Marseille, France.ORCID 0000-0003-4088-8238
Camille MailhacDrug discovery department, Enterome, Paris, France.
Valentine ThomasDrug discovery department, Enterome, Paris, France.ORCID 0009-0006-9530-5043
Stephanie BlumNestle Institute of Health Science, Lausanne, Switzerland.
Gregoire ChevalierDrug discovery department, Enterome, Paris, France.ORCID 0000-0003-4698-1206
Hélène ToussaintDrug discovery department, Enterome, Paris, France.
Souphalone LuangsayNestle Institute of Health Science, Lausanne, Switzerland.ORCID 0009-0005-8236-3300
Christophe BonnyDrug discovery department, Enterome, Paris, France.ORCID 0009-0006-8890-0290
Laurent CheneDrug discovery department, Enterome, Paris, France.ORCID 0009-0006-2436-0520
Antonietta CultroneDrug discovery department, Enterome, Paris, France.ORCID 0009-0000-4706-9599

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiota plays a pivotal role in modulating the immune system, fostering immune tolerance, and defending against pathogens. Among its bioactive products, microbiota-derived peptides hold therapeutic promise for inflammatory diseases. In this study, we present EB1010, a 28-residue peptide derived from an unknown protein of a Christensenellaceae bacterium, as potential treatment of ulcerative colitis (UC). EB1010 exhibit strong anti-inflammatory effects

Indexed as

Anti-Inflammatory AgentsColitis, UlcerativeEubacterialesPeptidesAdministration, OralAnimalsCaco-2 CellsDisease Models, AnimalHumansIntestinal MucosaMaleMiceNF-kappa BRatsRats, Sprague-DawleyTrinitrobenzenesulfonic AcidAnti-Inflammatory AgentsNF-kappa BPeptidesTrinitrobenzenesulfonic Acidanti-inflammatory peptidesgut microbiotaUlcerative colitis

Identifiers

PMID42033239
PMCPMC13114140

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.